Pender Fund Capital Management Ltd. Neoleukin Therapeutics, Inc. Transaction History

Pender Fund Capital Management Ltd.

  • $132 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.5 - $0.72 $3,354 - $4,830
6,709 New
6,709 $6,000

Others Institutions Holding NLTX

# of Institutions
1
Shares Held
199K
Call Options Held
0
Put Options Held
0
View Full List

About Neoleukin Therapeutics, Inc.

NLTX Quotes by TradingView
  • Ticker NLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,579,900
  • Description
  • Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...
More about NLTX
Track This Portfolio

Track Pender Fund Capital Management Ltd. Portfolio

Follow Pender Fund Capital Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pender Fund Capital Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Pender Fund Capital Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email